tiprankstipranks
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
US Market
TMDX
TransMedics Group
RESEARCH TOOLSreports
Want to see TMDX full AI Analyst Report?

TransMedics Group (TMDX) Stock Forecast & Price Target

1,891 Followers
See the Price Targets and Ratings of:

TMDX Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
7 Buy
4 Hold
0 Sell
Based on 11 analysts giving stock ratings to
TransMedics
Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TMDX Stock 12 Month Forecast

Average Price Target

$93.11
▲(0.97% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $93.11 with a high forecast of $122.00 and a low forecast of $65.00. The average price target represents a 0.97% change from the last price of $92.22.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"$64","151":"$151","85.75":"$85.8","107.5":"$107.5","129.25":"$129.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$122.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.11111111111111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$93.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,85.75,107.5,129.25,151],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.24,85.29846153846154,88.35692307692307,91.41538461538461,94.47384615384615,97.53230769230768,100.59076923076923,103.64923076923077,106.7076923076923,109.76615384615384,112.82461538461538,115.88307692307691,118.94153846153846,{"y":122,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.24,83.07623931623931,83.91247863247862,84.74871794871794,85.58495726495727,86.42119658119658,87.2574358974359,88.09367521367521,88.92991452991453,89.76615384615384,90.60239316239316,91.43863247863248,92.2748717948718,{"y":93.11111111111111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.24,80.91384615384615,79.58769230769231,78.26153846153846,76.9353846153846,75.60923076923076,74.28307692307692,72.95692307692308,71.63076923076923,70.30461538461539,68.97846153846154,67.65230769230769,66.32615384615384,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":111.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.89,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.01,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.53,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.51,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.24,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$122.00Average Price Target$93.11Lowest Price Target$65.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on TMDX
Josh Jennings
TD Cowen
TD Cowen
$120
Buy
30.12%
Upside
Reiterated
09/02/26
Analyst Reiterates Buy on TransMedics as U.S. Transplant Volumes Accelerate and Aviation Utilization Supports Sustained Growth
Piper Sandler Analyst forecast on TMDX
Matthew O'Brien
Piper Sandler
Piper Sandler
$100→$90
Buy
-2.41%
Downside
Reiterated
09/02/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Medtronic (NYSE: MDT) and AbCellera Biologics (NASDAQ: ABCL)
Oppenheimer Analyst forecast on TMDX
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and NeoGenomics (NASDAQ: NEO)
Stifel Nicolaus Analyst forecast on TMDX
Thomas Stephan
Stifel Nicolaus
Stifel Nicolaus
$65
Hold
-29.52%
Downside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Spyre Therapeutics (NASDAQ: SYRE) and COMPASS Pathways (NASDAQ: CMPS)
Canaccord Genuity Analyst forecast on TMDX
William Plovanic
Canaccord Genuity
Canaccord Genuity
$95
Buy
3.01%
Upside
Reiterated
08/12/26
TransMedics Buy Rating Reaffirmed as Analyst Maintains $95 Price Target on Robust Multi-Year Growth Outlook
J.P. Morgan Analyst forecast on TMDX
Allen Gong
J.P. Morgan
J.P. Morgan
$73
Hold
-20.84%
Downside
Reiterated
08/06/26
J.P. Morgan Sticks to Its Hold Rating for TransMedics Group (TMDX)
Robert W. Baird Analyst forecast on TMDX
David Rescott
Robert W. Baird
Robert W. Baird
$120→$122
Buy
32.29%
Upside
Reiterated
08/05/26
TransMedics price target raised to $122 from $120 at BairdTransMedics price target raised to $122 from $120 at Baird
UBS Analyst forecast on TMDX
Patrick Wood
UBS
UBS
$80→$77
Hold
-16.50%
Downside
Assigned
08/05/26
TransMedics price target lowered to $77 from $80 at UBSTransMedics price target lowered to $77 from $80 at UBS
William Blair Analyst forecast on TMDX
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and TransMedics Group (NASDAQ: TMDX)
Needham Analyst forecast on TMDX
Michael Matson
Needham
Needham
$142→$106
Buy
14.94%
Upside
Assigned
08/03/26
TransMedics Group: Robust Transplant Demand Supports Buy Rating Despite Price Target Cut to $106
Evercore ISI Analyst forecast on TMDX
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
$100→$90
Buy
-2.41%
Downside
Reiterated
07/06/26
TransMedics price target lowered to $90 from $100 at Evercore ISITransMedics price target lowered to $90 from $100 at Evercore ISI
Jefferies Analyst forecast on TMDX
Young Li
Jefferies
Jefferies
$145
Buy
57.23%
Upside
Reiterated
10/28/25
Jefferies Sticks to Its Buy Rating for TransMedics Group (TMDX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on TMDX
Josh Jennings
TD Cowen
TD Cowen
$120
Buy
30.12%
Upside
Reiterated
09/02/26
Analyst Reiterates Buy on TransMedics as U.S. Transplant Volumes Accelerate and Aviation Utilization Supports Sustained Growth
Piper Sandler Analyst forecast on TMDX
Matthew O'Brien
Piper Sandler
Piper Sandler
$100→$90
Buy
-2.41%
Downside
Reiterated
09/02/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Medtronic (NYSE: MDT) and AbCellera Biologics (NASDAQ: ABCL)
Oppenheimer Analyst forecast on TMDX
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and NeoGenomics (NASDAQ: NEO)
Stifel Nicolaus Analyst forecast on TMDX
Thomas Stephan
Stifel Nicolaus
Stifel Nicolaus
$65
Hold
-29.52%
Downside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Spyre Therapeutics (NASDAQ: SYRE) and COMPASS Pathways (NASDAQ: CMPS)
Canaccord Genuity Analyst forecast on TMDX
William Plovanic
Canaccord Genuity
Canaccord Genuity
$95
Buy
3.01%
Upside
Reiterated
08/12/26
TransMedics Buy Rating Reaffirmed as Analyst Maintains $95 Price Target on Robust Multi-Year Growth Outlook
J.P. Morgan Analyst forecast on TMDX
Allen Gong
J.P. Morgan
J.P. Morgan
$73
Hold
-20.84%
Downside
Reiterated
08/06/26
J.P. Morgan Sticks to Its Hold Rating for TransMedics Group (TMDX)
Robert W. Baird Analyst forecast on TMDX
David Rescott
Robert W. Baird
Robert W. Baird
$120→$122
Buy
32.29%
Upside
Reiterated
08/05/26
TransMedics price target raised to $122 from $120 at BairdTransMedics price target raised to $122 from $120 at Baird
UBS Analyst forecast on TMDX
Patrick Wood
UBS
UBS
$80→$77
Hold
-16.50%
Downside
Assigned
08/05/26
TransMedics price target lowered to $77 from $80 at UBSTransMedics price target lowered to $77 from $80 at UBS
William Blair Analyst forecast on TMDX
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and TransMedics Group (NASDAQ: TMDX)
Needham Analyst forecast on TMDX
Michael Matson
Needham
Needham
$142→$106
Buy
14.94%
Upside
Assigned
08/03/26
TransMedics Group: Robust Transplant Demand Supports Buy Rating Despite Price Target Cut to $106
Evercore ISI Analyst forecast on TMDX
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
$100→$90
Buy
-2.41%
Downside
Reiterated
07/06/26
TransMedics price target lowered to $90 from $100 at Evercore ISITransMedics price target lowered to $90 from $100 at Evercore ISI
Jefferies Analyst forecast on TMDX
Young Li
Jefferies
Jefferies
$145
Buy
57.23%
Upside
Reiterated
10/28/25
Jefferies Sticks to Its Buy Rating for TransMedics Group (TMDX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
BLTEBelite Bio, Inc. ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TransMedics Group

3 Months
William PlovanicCanaccord Genuity
Success Rate
23/40 ratings generated profit
57%
Average Return
+9.97%
Copying William Plovanic's trades and holding each position for 3 Months would result in 57.50% of your transactions generating a profit, with an average return of +9.97% per trade.
1 Year
William PlovanicCanaccord Genuity
Success Rate
23/40 ratings generated profit
57%
Average Return
+31.57%
Copying William Plovanic's trades and holding each position for 1 Year would result in 57.50% of your transactions generating a profit, with an average return of +31.57% per trade.
2 Years
William PlovanicCanaccord Genuity
Success Rate
21/40 ratings generated profit
53%
Average Return
+55.23%
Copying William Plovanic's trades and holding each position for 2 Years would result in 52.50% of your transactions generating a profit, with an average return of +55.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TMDX Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
15
16
16
10
7
Buy
8
6
5
9
10
Hold
6
9
8
10
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
31
29
29
23
In the current month, TMDX has received 17 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. TMDX average Analyst price target in the past 3 months is 93.11.
Each month's total comprises the sum of three months' worth of ratings.

TMDX Financial Forecast

TMDX Earnings Forecast

Next quarter’s earnings estimate for TMDX is $0.30 with a range of $0.15 to $0.40. The previous quarter’s EPS was $0.44. TMDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TMDX has Performed in-line its overall industry.
Next quarter’s earnings estimate for TMDX is $0.30 with a range of $0.15 to $0.40. The previous quarter’s EPS was $0.44. TMDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TMDX has Performed in-line its overall industry.

TMDX Sales Forecast

Next quarter’s sales forecast for TMDX is $177.03M with a range of $169.90M to $188.45M. The previous quarter’s sales results were $189.95M. TMDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TMDX has Performed in-line its overall industry.
Next quarter’s sales forecast for TMDX is $177.03M with a range of $169.90M to $188.45M. The previous quarter’s sales results were $189.95M. TMDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TMDX has Performed in-line its overall industry.

TMDX Stock Forecast FAQ

What is TMDX’s average 12-month price target, according to analysts?
Based on analyst ratings, TransMedics Group Inc’s 12-month average price target is 93.11.
    What is TMDX’s upside potential, based on the analysts’ average price target?
    TransMedics Group Inc has 0.97% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TMDX a Buy, Sell or Hold?
          TransMedics Group Inc has a consensus rating of Moderate Buy which is based on 7 buy ratings, 4 hold ratings and 0 sell ratings.
            What is TransMedics Group Inc’s price target?
            The average price target for TransMedics Group Inc is 93.11. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $122.00 ,the lowest forecast is $65.00. The average price target represents 0.97% Increase from the current price of $92.22.
              What do analysts say about TransMedics Group Inc?
              TransMedics Group Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of TMDX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.